This cannabis company produces organic, pharmaceutical-grade cannabidiol (CBD) oils to supply its product lines and to sell to third parties.
Some good news for Flora as Germany i is positioning itself as the Cannibus Eldarado for business opportunities
Flora completes acquisition of Franchise Global Health. This deal gives Flora access to the medical cannabis market in Germany (currently around 150k patients)
It is going to be a nervy few months for us FGC holders given the nasdaq deadline to get from 20c to $1. Likely it is my unabashed optimisim but Colombia’s move to become the first country to pay for cannabinoid prescriptive medicine (where Flora is HQ’d) is the only encouraging sign I need to hold onto hope!
A very clear breakdown of Flora Growth’s projection of between $90m-$105m in 2023. Also a really helpful breakdown of last year’s activities
When does the share value need to increase by to avoid delisting ? I’m new to all of this.
One dollar by June I think
1 Like
This’ll explain the criteria for delisting and Flora better than my previous reply, although I suspect the article is missing some additional nuance to the situation
1 Like
Update on Flora’s new sales
Not that the shsre price is benifitting, but news of Flora’s 300%+ growth in last quarter
Flora’s year end report in video, includes CEO, CFO and CMO. Helpfully breaks down all Flora’s M&A activity and areas for growth.
https://www.floragrowth.com/flora-growths-fiscal-year-2022-earnings-results-webcast-recording/
Flora have compound approved for prescriptions in Colombia
This will do a wealth of good for Flora if it hits the floor soon
Lost all hope in these now
Anyone have news on why these have fell. Heavily